The Hydroponics Company (ASX:THC) continues with the company strategy to leverage itself to the rapidly growing international marketplace for medical cannabis.
The company's executive team recently completed international meetings held in Europe, Israel and Canada.
THC noted that Canada and the European region continue to show strong growth in the supply and uptake of medicinal cannabis with both markets offering opportunities for the company.
Several potential partners have been identified for a range of medical solutions, with contract negotiations underway with several of these prospects.
In Israel, THC engaged with companies that have been producing CBD/THC strains for over 10 years and are looking to work with THC in Australia to fast track THC’s growing and manufacturing capabilities.
Alan Beasley, chairman, commented:
"Through the efforts of the THC management team visiting Europe Israel and Canada, the foundation has been laid for THC to access medicinal cannabis that has been in production and supplied for over ten years."
Medicinal Cannabis Medicines Portal
THC added that it is well advanced in discussions with potential suppliers of medicinal product and is targeting a medicinal cannabis product supply being available for dispensing in time for the Medicinal Cannabis Medicines Portal (MCMP) rollout later this year.
The MCMP is a collaborative approach between prescribers, pharmacists and sponsors to help patients get timely access to appropriate medicinal cannabis treatment in-line with all applicable National and State/Territory based laws and requirements.
READ NOW: The Hydroponics Company enters partnership facilitated at dispensing medicinal cannabis
THC is a foundation Sponsor of the MCMP.